Exelixis
EXEL
#1660
Rank
NZ$17.35 B
Marketcap
$60.76
Share price
1.26%
Change (1 day)
70.39%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Market capitalization of Exelixis (EXEL)

Market cap: NZ$17.35 Billion

As of November 2024 Exelixis has a market cap of NZ$17.35 Billion. This makes Exelixis the world's 1660th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.

Market cap history of Exelixis from 2000 to 2024

End of year Market Cap

Year Marketcap Change
2024NZ$17.35 B47.09%
2023NZ$11.79 B44.76%
2022NZ$8.14 B-3.76%
2021NZ$8.46 B-1.88%
2020NZ$8.62 B8.56%
2019NZ$7.94 B-9.6%
2018NZ$8.79 B-30.56%
2017NZ$12.66 B102.93%
2016NZ$6.24 B232.2%
2015NZ$1.87 B421.77%
2014NZ$0.36 B-73.85%
2013NZ$1.37 B34.89%
2012NZ$1.02 B24.08%
2011NZ$0.82 B-29.28%
2010NZ$1.16 B6.21%
2009NZ$1.09 B19.88%
2008NZ$0.91 B-22.59%
2007NZ$1.18 B-3.77%
2006NZ$1.22 B6.68%
2005NZ$1.14 B15.13%
2004NZ$0.99 B29.13%
2003NZ$0.77 B-14.82%
2002NZ$0.90 B-59.61%
2001NZ$2.24 B45.72%
2000NZ$1.54 B

End of Day market cap according to different sources

On Nov 9th, 2024 the market cap of Exelixis was reported to be:

NZ$17.35 Billion
by Yahoo Finance info icon info icon
NZ$17.35 Billion
by CompaniesMarketCap info icon info icon
NZ$17.35 Billion
by Nasdaq info icon info icon

Market capitalization for similar companies or competitors

Name Marketcap Market cap differencediff. Country
NZ$124.09 B 615.21%๐Ÿ‡ฌ๐Ÿ‡ง UK
NZ$217.93 B 1,156.03%๐Ÿ‡ซ๐Ÿ‡ท France
NZ$436.37 B 2,414.92%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$184.04 B 960.69%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$293.06 B 1,588.99%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$627.38 B 3,515.77%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$253.79 B 1,362.70%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$44.6 M-99.74%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$0.87 B-94.96%๐Ÿ‡บ๐Ÿ‡ธ USA